bromhexine has been researched along with Severe Acute Respiratory Syndrome in 1 studies
Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744)
bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).
Severe Acute Respiratory Syndrome: A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hörnich, BF | 1 |
| Großkopf, AK | 1 |
| Schlagowski, S | 1 |
| Tenbusch, M | 1 |
| Kleine-Weber, H | 1 |
| Neipel, F | 1 |
| Stahl-Hennig, C | 1 |
| Hahn, AS | 1 |
1 other study available for bromhexine and Severe Acute Respiratory Syndrome
| Article | Year |
|---|---|
SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
Topics: Ambroxol; Amino Acid Substitution; Angiotensin-Converting Enzyme 2; Bromhexine; Cell Line; COVID-19; | 2021 |